China is the bigger Biosimilars market: $3 Bn against $671 Mn in 2023, about 4.4 times as large.
India grows faster: 27.9% a year, against 26.4%. The gap still grows from $2.3 Bn to $23 Bn by 2033.
Clinical research: 34 active trials in China, 4 in India.
| Measure |  China |  India |
|---|---|---|
| Market size, 2023 | $3 Bn | $671 Mn |
| Market size, 2033 projected | $30.9 Bn | $7.9 Bn |
| Growth a year (CAGR) | 26.4% | 27.9% |
| Money added, 2023–2033 | $27.9 Bn | $7.2 Bn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $2.11 | $0.46 |
| Active clinical trials | 34 | 4 |
| Full report | China report | India report |
Year by year, 2023 to 2033
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Biosimilars, China or India?
China is the bigger Biosimilars market: $3 Bn against $671 Mn in 2023, about 4.4 times as large.
Which grows faster in Biosimilars, China or India?
India grows faster: 27.9% a year, against 26.4%. The gap still grows from $2.3 Bn to $23 Bn by 2033.
More Biosimilars comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.